These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 25459392)

  • 1. A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
    Bergmann L; Maute L; Heil G; Rüssel J; Weidmann E; Köberle D; Fuxius S; Weigang-Köhler K; Aulitzky WE; Wörmann B; Hartung G; Moritz B; Edler L; Burkholder I; Scheulen ME; Richly H
    Eur J Cancer; 2015 Jan; 51(1):27-36. PubMed ID: 25459392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
    Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
    Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
    Geldart T; Chester J; Casbard A; Crabb S; Elliott T; Protheroe A; Huddart RA; Mead G; Barber J; Jones RJ; Smith J; Cowles R; Evans J; Griffiths G
    Eur Urol; 2015 Apr; 67(4):599-602. PubMed ID: 25465968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
    Haas M; Waldschmidt DT; Stahl M; Reinacher-Schick A; Freiberg-Richter J; Fischer von Weikersthal L; Kaiser F; Kanzler S; Frickhofen N; Seufferlein T; Dechow T; Mahlberg R; Malfertheiner P; Illerhaus G; Kubicka S; Abdul-Ahad A; Snijder R; Kruger S; Westphalen CB; Held S; von Bergwelt-Baildon M; Boeck S; Heinemann V
    Eur J Cancer; 2021 Mar; 146():95-106. PubMed ID: 33588150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Feng Y; Cardenes H; Wagner L; Brell JM; Cella D; Flynn P; Ramanathan RK; Crane CH; Alberts SR; Benson AB
    J Clin Oncol; 2011 Nov; 29(31):4105-12. PubMed ID: 21969502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
    Inal A; Kos FT; Algin E; Yildiz R; Dikiltas M; Unek IT; Colak D; Elkiran ET; Helvaci K; Geredeli C; Dane F; Balakan O; Kaplan MA; Durnali AG; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Kucukoner M; Ozkan M; Uncu D; Benekli M; Isikdogan A
    Neoplasma; 2012; 59(3):297-301. PubMed ID: 22329849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
    Dalgleish AG; Stebbing J; Adamson DJ; Arif SS; Bidoli P; Chang D; Cheeseman S; Diaz-Beveridge R; Fernandez-Martos C; Glynne-Jones R; Granetto C; Massuti B; McAdam K; McDermott R; Martín AJ; Papamichael D; Pazo-Cid R; Vieitez JM; Zaniboni A; Carroll KJ; Wagle S; Gaya A; Mudan SS
    Br J Cancer; 2016 Sep; 115(7):789-96. PubMed ID: 27599039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
    BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
    Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
    J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma.
    Rogers JE; Mizrahi JD; Xiao L; Mohindroo C; Shroff RT; Wolff R; Varadhachary GR; Javle MM; Overman M; Fogelman DR; Raghav KPS; Pant S; McAllister F
    Cancer Med; 2020 Aug; 9(15):5406-5415. PubMed ID: 32519420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
    Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
    Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
    O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
    Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
    Lee HS; Chung MJ; Park JY; Bang S; Park SW; Kim HG; Noh MH; Lee SH; Kim YT; Kim HJ; Kim CD; Lee DK; Cho KB; Cho CM; Moon JH; Kim DU; Kang DH; Cheon YK; Choi HS; Kim TH; Kim JK; Moon J; Shin HJ; Song SY;
    Medicine (Baltimore); 2017 Jan; 96(1):e5702. PubMed ID: 28072706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.
    Reni M; Cereda S; Milella M; Novarino A; Passardi A; Mambrini A; Di Lucca G; Aprile G; Belli C; Danova M; Bergamo F; Franceschi E; Fugazza C; Ceraulo D; Villa E
    Eur J Cancer; 2013 Nov; 49(17):3609-15. PubMed ID: 23899530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
    Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
    Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
    Schultheis B; Reuter D; Ebert MP; Siveke J; Kerkhoff A; Berdel WE; Hofheinz R; Behringer DM; Schmidt WE; Goker E; De Dosso S; Kneba M; Yalcin S; Overkamp F; Schlegel F; Dommach M; Rohrberg R; Steinmetz T; Bulitta M; Strumberg D
    Ann Oncol; 2017 Oct; 28(10):2429-2435. PubMed ID: 28961832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
    Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD
    Ann Oncol; 2016 Apr; 27(4):648-53. PubMed ID: 26802153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study.
    Nishida S; Ishikawa T; Egawa S; Koido S; Yanagimoto H; Ishii J; Kanno Y; Kokura S; Yasuda H; Oba MS; Sato M; Morimoto S; Fujiki F; Eguchi H; Nagano H; Kumanogoh A; Unno M; Kon M; Shimada H; Ito K; Homma S; Oka Y; Morita S; Sugiyama H
    Cancer Immunol Res; 2018 Mar; 6(3):320-331. PubMed ID: 29358173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.